We have further demonstrated the importance of both ETV4 and ETV5 expression in promoting efficient clonogenic regrowth in SCLC and identify the kinase inhibitor LY2874455 as a unique pan-FGFR inhibitor that blocks downstream MAPK and PI3K-Akt signaling in SCLC and demonstrates efficacy in curbing SCLC regrowth after cisplatin and etoposide challenge. Here, ETV5 is linked to small cell lung carcinoma.